---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-259703"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-06-05T20:30:16+00:00"
generated_at: "2026-06-05T20:37:36.063093+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics enters into $17.35M ATM equity distribution agreement with Canaccord Genuity

## Summary
- Up to $17.35M of common stock may be sold at-the-market through Canaccord Genuity as agent.
- Commission of 3.0% of gross proceeds plus $75,000 expense reimbursement to Agent.
- Proceeds intended for general corporate purposes and working capital.
- Sales may be made on Nasdaq Capital Market under Rule 415; no obligation to sell shares.
- Offering terminates upon sale of all shares or termination of Distribution Agreement.

## SEC filing metadata
- accession: 0001193125-26-259703
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-06-05T20:30:16+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526259703/0001193125-26-259703-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526259703/pstv-20260601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-259703
- JSON: https://secwatch.observer/filing/0001193125-26-259703.json
- Plain text: https://secwatch.observer/filing/0001193125-26-259703.txt

## Key facts
- Material Agreements
  PLUS THERAPEUTICS, INC. entered into Equity Distribution Agreement with Canaccord Genuity LLC valued at $17,350,000 (effective 2026-06-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Canaccord Genuity LLC
  - Value: $17,350,000
  - Effective: 2026-06-01
  source text: On June 1, 2026, Plus Therapeutics, Inc. (the “Company”) entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Canaccord Genuity LLC (the “Agent”), pursuant to which the Company may issue and sell, from time to time (the “Offering”), shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $17,350,000 (the “Shares”), depending on market demand, with the Agent acting as an agent for sales.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526259703/0001193125-26-259703-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.